Nirogacestat in Ovarian Granulosa Cell Tumors

Completed · Phase 2

Conditions studied: Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor, Ovarian Cancer

In brief

This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of ovarian granulosa tumors.

Key facts

Study ID
NCT05348356
Run by
SpringWorks Therapeutics, Inc.
People needed
53
Starts
2022-08-30
Expected to finish
2025-07-14
Last updated by the study team
2025-12-15

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.